FDA Snapshot: ICOTYDE Approved for Plaque Psoriasis
ICOTYDE, an IL-23 receptor antagonist, has been approved for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg.
Asset / Drug
Drug and asset intelligence for ICOTYDE with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.